Tissue factor pathway inhibitor (TFPI) is a plasma multivalent Kunitz-type serine protease inhibitor that interacts with FV, and this interaction may alter the formation of venous thrombosis (12) and may be related to cancer progression (13). The gene discussed is F5; the disease is cancer.